Synergy Pharmaceuticals’ Chairman and CEO, Dr. Gary S. Jacob, Awarded Honorary Degree by the University of Missouri – St.

  Synergy Pharmaceuticals’ Chairman and CEO, Dr. Gary S. Jacob, Awarded
  Honorary Degree by the University of Missouri – St. Louis

Business Wire

NEW YORK -- May 15, 2014

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chairman and
Chief Executive Officer, Dr. Gary S. Jacob, will be recognized and awarded
with the honorary degree, Doctor of Science Honoris Causa, from his alma
mater, the University of Missouri – St. Louis, at a commencement ceremony this
Saturday, May 17, 2014.

Dr. Gary S. Jacob, Chairman and CEO, Synergy Pharmaceuticals Inc. (Photo:
Business Wire)

Dr. Gary S. Jacob, Chairman and CEO, Synergy Pharmaceuticals Inc. (Photo:
Business Wire)

Dr. Jacob is one of only six recipients voted by UMSL to be awarded with one
of the highest honors the university bestows individuals. Honorary degree
recipients are nominated and then selected by the committee based on rendered
distinctive service, high achievement and commitment to excellence.

Dr. Jacob graduated with honors with a bachelor’s degree in chemistry in 1969
from UMSL and a PhD in biochemistry from the University of Wisconsin-Madison
in 1976. In 1991, he received UMSL’s Distinguished Alumni Award and this year
was named to the Chancellor’s Council. Dr. Jacob will receive his honorary
degree at the 2 p.m. ceremony on May 17^th in the Mark Twain Athletic and
Fitness Center on campus.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals (NASDAQ:SGYP) is a biopharmaceutical company focused
on the development of novel therapies based on the natural human hormone,
uroguanylin, to treat gastrointestinal diseases and disorders. Uroguanylin is
a natural hormone produced by humans in the small intestine and plays a key
role in regulating the normal functioning of the digestive tract through its
activity on the guanylate cyclase-C (GC-C) receptor. The GC-C receptor is
known to be a primary source for stimulating a variety of beneficial
physiological responses. Synergy has created two unique analogs of uroguanylin
– plecanatide and SP-333 – designed to mimic the natural hormone’s activity on
the GC-C receptor and target a variety of gastrointestinal conditions.
Plecanatide is currently in two pivotal phase 3 clinical trials for chronic
idiopathic constipation and has successfully completed a phase 2b dose-ranging
study in patients with irritable bowel syndrome with constipation. SP-333 is
currently in phase 2 development for opioid-induced constipation and is also
being explored for ulcerative colitis. For more information, please visit
www.synergypharma.com.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20140515005047/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50865065&lang=en

Contact:

Company:
Synergy Pharmaceuticals Inc.
Gem Gokmen, 212-584-7610
ggokmen@synergypharma.com
 
Press spacebar to pause and continue. Press esc to stop.